Feroze Momin, MD
Hematology & Oncology · Dearborn, MINPI 1396728507
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $217 of the $250 with a category attached, or 86.6%. It is spread thinly across 12 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $106 and has fallen 81.1% since, to $20 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 12 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$35
- Bristol Myers Squibb$28
- CTI Biopharma Corp.$25
- Rigel Pharmaceuticals, Inc.$24
- Merck$23
- Morphosys, US Inc.$23
- plus $92 from 6 others
What the payments were for
- Food & beverage$21787%
- Education$3413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $35 |
| Bristol Myers Squibb | 1 | $28 |
| CTI Biopharma Corp. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Morphosys, US Inc. | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $15 |
| Novartis | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Seagen Inc. | 1 | $14 |
How this compares
$250 in reported general payments places this provider in the 20th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 18 | $167,977 |
| Hydroxyurea | 17 | $709 |
| Letrozole | 49 | $642 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Dearborn
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.